(ANN ARBOR, Mich.) HandyLab, Inc. announced today that QIAGEN N.V. has licensed HandyLab extraction technology for use as part of QIAGEN’s sample technology solution designed for use in combination with QIAGEN’s HPV testing assays on its QIAensemble screening and QIAsymphony random access platforms.

“We are delighted to have QIAGEN as a partner. The cooperation with QIAGEN, a leader in molecular diagnostics and the world’s leading company in the rapidly growing market segment of HPV testing, provides HandyLab with strong growth potential from the use of our proprietary nucleic acid extraction technology,” Jeffrey Williams, president of HandyLab said.

About HandyLab, Inc.

HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products. HandyLab’s proprietary Jaguar System reduces the time, cost and complexity of testing, while improving quality of results. Using patented, real-time, microfluidic PCR technology, HandyLab’s products are positioned to decentralize nucleic acid testing. Additional information about the company can be found at www.handylab.com or by calling 1-866-HandyLab (1-866-426-3952).